A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France.

about

A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France.

Item

http://www.wikidata.org/entity/Q38598931

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

A cost-effectiveness analysis ...... ll-cell lung cancer in France.

@en

type

Item

label

A cost-effectiveness analysis ...... ll-cell lung cancer in France.

@en

prefLabel

A cost-effectiveness analysis ...... ll-cell lung cancer in France.

@en

P1476

A cost-effectiveness analysis ...... ll-cell lung cancer in France.

@en

P2093

Ghassan Sleilaty

http://www.w3.org/2001/XMLSchema#string

James Eaton

http://www.w3.org/2001/XMLSchema#string

Kaisa Taipale

http://www.w3.org/2001/XMLSchema#string

Katherine B Winfree

http://www.w3.org/2001/XMLSchema#string

Mark Boye

http://www.w3.org/2001/XMLSchema#string

Mickael Basson

http://www.w3.org/2001/XMLSchema#string

Rachel Evans

http://www.w3.org/2001/XMLSchema#string

P2860

Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.

Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial.

Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review.

Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

P304

505-518

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CEOR.S128371

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Christos Chouaid

P577

2017-08-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28860832

http://www.w3.org/2001/XMLSchema#string

P932

5566359

http://www.w3.org/2001/XMLSchema#string